Non-commercial trials on medicines submitted to the Ethics Committee of the University Hospital of Bologna (Italy) along 8 years of activity: time to update rules and recommendations
- 50 Downloads
In Italy, the non-commercial trials on medicines are regulated by the Ministry Decree 17 December, 2004. Its intent is of encouraging the independent research for the improvement of clinical practice. We aimed to analyze the main features of the proposals of non-commercial clinical trials on medicines submitted to the Independent Ethics Committee (IEC) of the University Hospital of Bologna in the period 2010–2017.
Data were extracted from IEC registry and were organized with an ad hoc database. The relationships between the variables were examined using contingency tables. When appropriate, we applied the chi-square statistical test for the comparison of the categorical variables.
Over the 8-year period, the IEC evaluated 2931 studies, of which 1156 (39.4%) related to clinical trials on medicines; 245 (21.2%) out of the latter were non-commercial ones. A percentage of 49.8 of the trials were of phase II; 137 trials (55.9%) were promoted by hospitals, medical schools or institutes for research, hospitalization and health care. Non-profit organizations and scientific societies were promoters of 88 trials (35.9%). Most phase I and phase II trials received additional support from pharmaceutical companies.
Our results show a not negligible industrial influence on non-commercial trials through additional support, mostly to those of phase II. An update of the present legislation on this matter is desirable, adopting clearer rules on the relations sponsor-industry.
KeywordsClinical trials regulation Non-commercial trials Non-profit organizations Pharmaceutical industry Ethics committee
Contributions to conception or design of the study (NM, DM, GB), analyzed data (NM, GB, SP, GC) or interpretation of data for the work (NM, DM, GC, SP); wrote the paper (NM, GB, DM) or revising it critically for important intellectual content (GC, SP); all the authors approved the submitted final version to be published and all the authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Compliance with ethical standards
The manuscript does not contain clinical trials or patient data. For this type of study, formal consent is not required but only notification to the Ethics Committee.
Conflict of interest
The authors declare that they have no conflict of interest.
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the position of the Ethics Committee, where four of us were (NM, DM, GC, SP) or are (GC, SP) in activity.
- 2.Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41–58. https://doi.org/10.1038/nrd.2018.168 CrossRefGoogle Scholar
- 3.Directive 2001/20/EC of The European Parliament and of the Council, available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf. Accessed 21 Feb 2019
- 5.Montanaro N. Studi no-profit sui farmaci: è tempo di una normativa 2.0. Evidence, December 2014, volume 6, issue 12, e1000099, available at: https://www.evidence.it/articoli/pdf/e1000099.pdf. Accessed 21 Feb 2019
- 6.Ministerial Decree 17.12.2004. Available at http://www.gidm.org/doc/DM_17_dicembre_2004.pdf. Accessed 21 Feb 2019
- 7.Document on clinical research by non-profit promoter (2018) available at: https://www.fadoi.org/wp-content/uploads/2018/11/FADOI.CRNP_.2018.Documento.propositivo.FINAL_.pdf. Accessed 21 Feb 2019
- 8.Montanaro N, Melis M, Proni S, Chiabrando G, Motola D (2017) Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations. Eur J Clin Pharmacol 73(4):479–485. https://doi.org/10.1007/s00228-016-2186-y CrossRefGoogle Scholar
- 9.11th National Report on Clinical Trials of Drugs in Italy, 2012. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/11_rapporto_lug_12_ita_0.pdf. Accessed 26 Oct 2016
- 10.12th National Report on Clinical Trials of Drugs in Italy, 2013. http://www.agenziafarmaco.gov.it/sites/default/files/12_Rapporto_dic%2013_ITA.pdf. Accessed 26 Oct 2016
- 11.National Monitoring Centre for Clinical Trials (OsSC) available at: http://www.agenziafarmaco.gov.it/content/osservatorio-nazionale-sulla-sperimentazione-clinica-dei-medicinali. Accessed 21 Feb 2019
- 15.Italian Law 11.01.2018 n. 3, available at: http://www.gazzettaufficiale.it/eli/id/2018/1/31/18G00019/sg. Accessed 21 Feb 2019
- 16.Http://www.senato.it/leg/18/BGT/Schede/docnonleg/37870.htm. Accessed 22 Feb 2019